Please login to the form below
Luxturna
This page shows the latest Luxturna news and features for those working in and with pharma, biotech and healthcare.
Novartis to pay up to $1.5bn for Gyroscope
With our own pioneering research in ocular gene therapies and our experience gained from bringing Luxturna to inherited retinal dystrophy patients outside of the US, Novartis has a well-established expertise
Latest news
-
bluebird bio lodges counterclaim against Spark Therapeutics
The biotech company became the first company to receive approval for a gene therapy in the US for its rare inherited retinal disease treatment Luxturna (voretigene neparvovec).
-
Allergan and Editas claim a CRISPR first in inherited blindness study
Although there is a gene therapy available for Leber’s – Spark’s Luxturna – it doesn’t work for the specific gene mutation which causes LCA10.
-
Roche moving closer to approval of Spark takeover; report
ongoing. Spark was the first company to win approval for a gene therapy in the US, and if the deal goes through Roche will secure rights to that product – Luxturna (voretigene
-
NICE backs NHS use of Novartis’ gene therapy Luxturna
First and only therapy for rare, inherited form of blindness. Novartis’ gene therapy Luxturna for a rare, inherited form of blindness should be available for routine NHS use in England and ... Luxturna (voretigene neparvovec) has been shown in clinical
-
Europe urged to adapt faster to gene therapy challenges
s Yescarta, plus Spark/Roche’s gene therapy Luxturna, and most recently, the approval of Bluebird’s gene therapy Zynteglo.
More from news
Approximately 7 fully matching, plus 30 partially matching documents found.
Latest Intelligence
-
Keeping up with the developing regulatory requirements for gene and cell therapies
By Clive Glover. Since the approval of the first five gene or gene-modified cell therapies in the US – Luxturna, Yescarta, Tecartus, Kymriah and Zolgensma – this new technology has been evolving
-
Bluebird: on a mission to ‘recode’ the DNA of healthcare
Meanwhile, Spark Therapeutics’ Luxturna for a hereditary eye disease (marketed by Novartis in Europe) costs around $425, 000 per eye, bringing it close to that $1m mark.
-
Cell and gene therapy
Cell and gene therapies are currently expensive to manufacture. We do not believe that recently marketed products, with US prices ranging from $373, 000 for Yescarta to $850, 000 for Luxturna,
-
Drug launches to watch in 2019
therapy Luxturna was also approved in Europe late in the year. ... Novartis has a deal with Spark to market Luxturna in Europe, and is therefore at the forefront of not only the groundbreaking R&D behind cell and gene therapy, but is
-
Bluebird Bio: on the cusp of a gene therapy revolution
drugs, Novartis’ Kymriah and Gilead/Kite’s Yescarta and Spark Therapeutics’ gene therapy Luxturna all reaching the market last year. ... Spark's Luxturna: already approved in the US, expected to gain EU approval by late 2018.
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- My journey advancing the science in pulmonary hypertension
- A new era for UK-Japanese scientific research relations
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- GSK announces The HealthTree Foundation’s multiple myeloma programme as first ‘Think Tank’ challenge winner
- NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
- Innovative Trials opens first US office
- Scanning for Health Indicators and Risks Through Your Smartphone
- Realising the potential of omnichannel in medical communications
- College of Medicine launches Beyond Pills campaign to tackle overprescribing in UK health system
- AI is transforming pharma R&D – now it can transform pharma marketing
- J&J’s Darzalex shows ‘significant’ survival benefit in newly diagnosed multiple myeloma
- Six UK universities receive grant for research into motor neurone disease
- My journey advancing the science in pulmonary hypertension
PMHub
OPEN Health
OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
